- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02624726
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment (MINOAS)
A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Colorectal cancer accounts for 8% of all malignant tumors in adults and is considered as a major cause of cancer morbidity and mortality worldwide. Although curative surgical resection is possible in 70-80% of patients at diagnosis, almost half of them will develop local or/and metastatic recurrence and will die of the disease with the liver been the most common site of metastatic spread from CRC.
Combinations of infusional administrated 5-fluorouracil/Leucovorin with irinotecan or oxaliplatin are accepted as the mainstay of first-line treatment and have increase the median overall survival of patients with advanced CRC from 12 months to about 21-22 months. In addition, resection for colorectal metastases (mainly in the liver), has become the standard of care, for patients with limited metastatic disease confounded to the liver and currently remains the only potentially curative therapy Aflibercept, also known as vascular endothelial growth factor (VEGF) Trap, is an angiogenesis inhibitor with a unique mechanism of action. Aflibercept is a recombinant fusion protein that consists of portions of human VEGFR1 and VEGFR2 extracellular domains fused to the Fc portion of human immunoglobulin G1. This fusion protein binds all forms of Vascular Endothelial Growth Factor-A, as well as VEGF-B and placental growth factor, additional angiogenic growth factors that appear to play a role in tumor angiogenesis and inflammation. Aflibercept has been shown to bind VEGF-A, VEGF-B, and placental growth factor (PlGF) with higher affinity than their native receptors. In vitro and in vivo studies have shown that aflibercept can inhibit new vessel growth and tumor vascularization in tumor models.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Athens, Grekland
- 251 Air Forces Military Hospital of Athens
-
Athens, Grekland
- Anicancer Hospital of Athens "Agios Savvas"
-
Athens, Grekland
- Anticanscer Hospital of Athens "Agios Savvas"
-
Athens, Grekland
- Athens Hospital "Mitera" Hygia Polis
-
Athens, Grekland
- General Hospital of Athens "Aretaieio"
-
Athens, Grekland
- General Hospital of Athens "Sotiria"
-
Athens, Grekland
- IASO general hospital
-
Río, Grekland
- University Hospital of Patras-Rio
-
Thessaloniki, Grekland
- Thessaloniki Bioclinic
-
-
Crete
-
Heraklion, Crete, Grekland, 71110
- University Hospital of Heraklion Crete
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients with histologically documented adenocarcinomas of colon or rectum with unresectable metastatic disease.
- No prior treatment for metastatic disease
- Metastatic liver disease assessable with diffusion-weighted Magnetic Resonance Imaging (MRI)
- No previous treatment with bevacizumab or Cetuximab or Panitumumab.
- Patients may have receive fluoropyrimidines with or without oxaliplatin as adjuvant treatment, if they have progressed > 12 months after the end of the last cycle of the adjuvant treatment
- Performance Status (ECOG) 0-2
- Life expectancy ≥ 3 months.
- Effective contraception for both male and female subjects if the risk of conception exists.
- Adequate laboratory parameters: Absolute neutrophils count ≥ 1.5 x 109 /L, Platelets ≥ 100 x 109 /L, Leucocytes > 3,000/mm; Hemoglobin> 10.5g/dl, creatinine clearance ≥ 60 ml/min, Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour, Magnesium ≥ lower limit of normal, Calcium ≥ lower limit of normal, total Bilirubin ≤ 1.5 times the upper limit of normal; aspartate and alanine aminotransferase ≤ 3 times of the upper normal limit in absence of liver metastases, or ≤5x Upper Normal Limits (UNL) in presence of liver metastases, alkaline phosphatases < 5x UNL
- All patients will have to sign written informed consent in order to participate in the study.
- Female patients must commit to using reliable and appropriate methods of contraception until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial
Exclusion Criteria:
- Known hypersensitivity reaction to the component of the treatment.
- Inability to underwent a diffusion-weighted MR Imaging at baseline and in predefined time points
- Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- History or evidence upon physical examination of Central Nervous System (CNS) metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy),
- Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy),
- Treatment with any other investigational medicinal product within 28 days prior to study entry.
- Other serious and uncontrolled non-malignant disease
- Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy.
- Gilbert's syndrome
- Intolerance to atropine sulfate or loperamide
- Known dihydropyrimidine dehydrogenase deficiency
- Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization
- Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis
- Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days
- INR in absence of anticoagulation therapy > 1.25 or poorly controlled anti-coagulation therapy on coumadin or heparin compounds (INR >3.0)
- History of myocardial infarction and/or stroke within 6 months prior to randomization, New York Heart Association (NYHA) class III and IV congestive heart failure
- History of life threatening (grade 4) venous thromboembolic events (including pulmonary embolism) within 6 months prior to registration,
- Bowel obstruction
- Legal incapacity or limited legal capacity.
- Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent.
- A second primary tumour other than non-melanoma skin cancer or in situ cervical cancer.
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on chest CT scan.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: FOLFIRI/Aflibercept
5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
|
5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
Andra namn:
Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
Andra namn:
Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
Andra namn:
Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Total svarsfrekvens
Tidsram: Sjukdomsutvärdering vecka 8
|
Sjukdomsutvärdering vecka 8
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Total överlevnad
Tidsram: 1 år
|
1 år
|
|
Progressionsfri överlevnad
Tidsram: 1 år
|
1 år
|
|
Toxicity profile (CTCAE v4.0)
Tidsram: Every 2 weeks up to 100 weeks
|
From date of randomization until the date of last follow up or death from any cause, assessed up to 100 weeks
|
Every 2 weeks up to 100 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: John Souglakos, MD, Hellenic Oncology Research Group
- Huvudutredare: Athanasios Kotsakis, MD, Hellenic Oncology Research Group
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Gastrointestinala sjukdomar
- Kolonsjukdomar
- Tarmsjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolorektala neoplasmer
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Skyddsmedel
- Topoisomerasinhibitorer
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Mikronäringsämnen
- Vitaminer
- Topoisomeras I-hämmare
- Motgift
- Vitamin B-komplex
- Fluorouracil
- Leucovorin
- Irinotekan
- Levoleucovorin
- Aflibercept
Andra studie-ID-nummer
- CT/14.01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metastaserande kolorektal cancer
-
I-Mab Biopharma Co. Ltd.Inte längre tillgängligSolid Tumor Metastatic Cancer Advanced Cancer
-
PfizerAvslutadBRAF eller NRAS Mutant Metastatic MelanomFörenta staterna, Nederländerna, Italien, Tyskland, Schweiz
-
Sunnybrook Health Sciences CentrePfizerAvslutadClear Cell Metastatic Renal Cell CarcinomKanada
-
Association Pour La Recherche des Thérapeutiques...AvslutadClear Cell Metastatic Renal Cell CarcinomFrankrike
-
Incyte CorporationMerck Sharp & Dohme LLCAvslutadMelanom | Lymfom | Huvud- och halscancer | Magcancer | Äggstockscancer | Hepatocellulärt karcinom (HCC) | Lungcancer | Blåscancer | Endometriecancer | Fasta tumörer | Njurcellscancer (RCC) | Trippel negativ bröstcancer (TNBC) | UC (Urotelial cancer) | Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Förenta staterna
Kliniska prövningar på 5 Fluorouracil
-
The Netherlands Cancer InstituteAvslutad
-
The Netherlands Cancer InstituteAvslutad
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMucinöst adenokarcinom i ändtarmen | Steg IIA rektal cancer | Steg IIB rektal cancer | Steg IIC rektal cancer | Steg IIIB rektal cancer | Steg IIIC rektal cancerFörenta staterna
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.OkändSkivepitelcancer i huvud och nackeKina
-
National Cancer Institute (NCI)AvslutadSteg IV tjocktarmscancer | Steg IV rektal cancer | Återkommande tjocktarmscancer | Återkommande rektalcancer | Adenocarcinom i ändtarmen | Adenocarcinom i tjocktarmenFörenta staterna
-
The Cleveland ClinicNational Cancer Institute (NCI)AvslutadAktinisk keratos | Organ- eller vävnadstransplantation; KomplikationerFörenta staterna
-
Singapore National Eye CentreSingapore Eye Research Institute; Nanchang UniversityAvslutadGlaukom | Sårläkning | TrabekulektomiSingapore
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AvslutadKolorektal cancer | Metastaserande cancerFörenta staterna
-
National Cancer Institute (NCI)AvslutadAdenocarcinom i ändtarmen | Steg II rektal cancer | Steg III rektal cancerFörenta staterna